Siemens’ Dx Quality Control Called Out In Three FDA Warning Letters
This article was originally published in The Gray Sheet
The letters, based on inspections carried out at three different facilities between October 2011 and February 2012, cite numerous violations involving the firm’s complaint handling and other quality-control procedures.
You may also be interested in...
The Israeli biotech which is listed on the NASDAQ is in for a busy 2021 with strong marketing pushes for Movantik, Aemcolo and Talicia and completing a pivotal trial for COVID-19 hopeful opaganib.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
To increase transparency and affordability, American billionaire and businessman Mark Cuban has launched a US generics venture under the name ‘the Mark Cuban Cost Plus Drugs Company.’ Cuban’s new company is hoping to introduce over 100 drugs by the end of 2021 and build a pharmaceutical factory of its own by 2022.